Open AccessProspective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder
Author(s) -
Lode J. Swinnen,
Michael LeBlanc,
Thomas M. Grogan,
Gordon Li,
Patrick J. Stiff,
Alan M. Miller,
Yvette L. Kasamon,
Thomas P. Miller,
Richard I. Fisher
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181761659
Subject(s) - medicine , rituximab , immunosuppression , chemotherapy , gastroenterology , surgery , tacrolimus , biopsy , transplantation , lymphoma
Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab.